Anesthesia Clinical Trial
— SECUREOfficial title:
A Multicenter, Prospective, Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety in Non-interventional, Real-world Setting
NCT number | NCT05788718 |
Other study ID # | BR-SGD-OS-401 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 11, 2023 |
Est. completion date | August 2025 |
The purpose of this observational study is to evaluate patients who are planning to administer sugammadex after rocuronium or vecuronium is used. The main questions it aims to answer are: 1. Prescription pattern of sugammadex 2. Effectiveness and safety of sugammadex Since this study is observational, only data generated under daily treatment are to be collected, and no additional tests or drug administration is conducted for the study. The patients are observed from baseline to 24 hours after the initial administration of sugammadex.
Status | Recruiting |
Enrollment | 7000 |
Est. completion date | August 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - Male or female adults aged 19 or older - Is to undergo elective surgery under general anesthesia - Is planned to use rocuronium or vecuronium as an NMBA - Is planned for extubation before/after being moved to the recovery room - ASA physical status I - III - Patients who have signed the informed consent after receiving information about the purpose and method of this study Exclusion Criteria: - Has myasthenia gravis or Eaton-Lambert myasthenic syndrome - Has hypersensitivity to ingredients of sugammadex, rocuronium, or vecuronium - Has received an investigational product within 12 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study. - Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Korea University Anam Hospital | Seoul | Seongbuk-gu |
Lead Sponsor | Collaborator |
---|---|
Boryung Pharmaceutical Co., Ltd |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Re-administration rate of sugammadex | The number and ratio of patients re-administered with sugammadex within 24 hours of the initial administration of sugammadex are evaluated. | baseline~24 hours after administration | |
Secondary | Prescription pattern of sugammadex | The ratio of patients is presented for each administered time and dose. | baseline~24 hours after administration | |
Secondary | Incidence rate of postoperative residual curarization (PORC)(TOFr<0.9) | The TOFr (train-of-four ratio) is measured at 3 and 30 minutes after administration of sugammadex. The number and ratio of patients with a TOFr <0.9 are defined as PORC(TOFr<0.9). The TOFr is expressed as a decimal from 0.0 up to 1.0. | at 3 and 30 minutes after administration of sugammadex | |
Secondary | Incidence rate of postoperative residual curarization (PORC)(TOFr<1.0) | The TOFr (train-of-four ratio) is measured at 3 and 30 minutes after administration of sugammadex. The number and ratio of patients with a TOFr <1.0 are defined as PORC(TOFr<1.0). The TOFr is expressed as a decimal from 0.0 up to 1.0. | at 3 and 30 minutes after administration of sugammadex | |
Secondary | Analysis of clinical factors affecting sugammadex re-administration | The number and ratio of patients who had these clinical factors are evaluated. | baseline~24 hours after administration | |
Secondary | Incidence rate of respiratory complications related to postoperative residual muscle relaxation after surgery | The number and ratio of patients who had respiratory complications related to postoperative residual muscle relaxation after surgery are evaluated. | time from the first administration of sugammadex ~ 24 hours after administration | |
Secondary | TOFr before sugammadex administration | The TOFr (train-of-four ratio) is measured before each administration of sugammadex. The TOFr is expressed as a decimal from 0.0 up to 1.0. | baseline~24 hours after administration | |
Secondary | TOFr before extubation | The TOFr (train-of-four ratio) is measured before extubation. The TOFr is expressed as a decimal from 0.0 up to 1.0. | baseline~24 hours after administration | |
Secondary | Time to extubation | The time from the first administration of sugammadex or the last administration of NMBA to the time of extubation is measured in minutes. | baseline~24 hours after administration | |
Secondary | Time surpassed from the expected dismissal time from the recovery room | The time of dismissal from the recovery room is recorded for each patient. | baseline~24 hours after administration | |
Secondary | Ratio of unplanned transfer to the intensive care unit(excluding lung surgery and heart surgery) | The number and ratio of patients who was moved from the recovery room to the intensive care unit unplanned. | time from the first administration of sugammadex ~ 24 hours after administration | |
Secondary | Incidence rate of PONV(postoperative nausea and vomiting) | The number and ratio of patients who experiences PONV(postoperative nausea and vomiting). | time from the first administration of sugammadex ~ 24 hours after administration | |
Secondary | Incidence rate of adverse drug reaction | The number and ratio of patients who experiences adverse drug reactions in which their relationship to sugammadex cannot be ruled out. | time from the first administration of sugammadex ~ 24 hours after administration | |
Secondary | Incidence rate of serious adverse drug reaction | The number and ratio of patients who experiences serious adverse drug reactions in which their relationship to sugammadex cannot be ruled out. | time from the first administration of sugammadex ~ 24 hours after administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04279054 -
Decreased Neuraxial Morphine After Cesarean Delivery
|
Early Phase 1 | |
Active, not recruiting |
NCT04580030 -
Tricuapid Annular Plane Sistolic Excursion Before General Anesthesia Can Predict Hypotension After Induction
|
||
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Recruiting |
NCT04099693 -
A Prospective Randomized Study of General Anesthesia Versus Anesthetist Administered Sedation for ERCP
|
||
Terminated |
NCT02481999 -
Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years
|
||
Completed |
NCT04235894 -
An Observer Rating Scale of Facial Expression Can Predict Dreaming in Propofol Anesthesia
|
||
Recruiting |
NCT05525104 -
The Effect of DSA on Recovery of Anaesthesia in Children (Het Effect Van DSA op Het Herstel na Anesthesie Bij Kinderen).
|
N/A | |
Recruiting |
NCT05024084 -
Desflurane and Sevoflurane Minimal Flow Anesthesia on Recovery and Anesthetic Depth
|
Phase 4 | |
Completed |
NCT04204785 -
Noise in the OR at Induction: Patient and Anesthesiologists Perceptions
|
N/A | |
Completed |
NCT03277872 -
NoL, HR and MABP Responses to Tracheal Intubation Performed With MAC Blade Versus Glidescope
|
N/A | |
Terminated |
NCT03940651 -
Cardiac and Renal Biomarkers in Arthroplasty Surgery
|
Phase 4 | |
Terminated |
NCT02529696 -
Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers
|
||
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Terminated |
NCT03704285 -
Development of pk/pd Model of Propofol in Patients With Severe Burns
|
||
Recruiting |
NCT05259787 -
EP Intravenous Anesthesia in Hysteroscopy
|
Phase 4 | |
Completed |
NCT02894996 -
Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient?
|
N/A | |
Completed |
NCT05386082 -
Anesthesia Core Quality Metrics Consensus Delphi Study
|
||
Terminated |
NCT03567928 -
Laryngeal Mask in Upper Gastrointestinal Procedures
|
N/A | |
Recruiting |
NCT06074471 -
Motor Sparing Supraclavicular Block
|
N/A | |
Completed |
NCT04163848 -
CARbon Impact of aNesthesic Gas
|